- Home
- FTRK vs ACTU Comparison
FTRK vs ACTU Comparison
Compare FTRK & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTRK
- ACTU
- Stock Information
- Founded
- FTRK 2012
- ACTU 2015
- Country
- FTRK Singapore
- ACTU United States
- Employees
- FTRK N/A
- ACTU N/A
- Industry
- FTRK
- ACTU
- Sector
- FTRK
- ACTU
- Exchange
- FTRK NYSE
- ACTU NYSE
- Market Cap
- FTRK 134.1M
- ACTU 135.0M
- IPO Year
- FTRK 2025
- ACTU 2024
- Fundamental
- Price
- FTRK $0.71
- ACTU $6.55
- Analyst Decision
- FTRK
- ACTU Strong Buy
- Analyst Count
- FTRK 0
- ACTU 1
- Target Price
- FTRK N/A
- ACTU $20.00
- AVG Volume (30 Days)
- FTRK 2.0M
- ACTU 143.8K
- Earning Date
- FTRK 01-01-0001
- ACTU 05-15-2025
- Dividend Yield
- FTRK N/A
- ACTU N/A
- EPS Growth
- FTRK N/A
- ACTU N/A
- EPS
- FTRK N/A
- ACTU N/A
- Revenue
- FTRK $117,230.00
- ACTU N/A
- Revenue This Year
- FTRK N/A
- ACTU N/A
- Revenue Next Year
- FTRK N/A
- ACTU N/A
- P/E Ratio
- FTRK N/A
- ACTU N/A
- Revenue Growth
- FTRK 2589.48
- ACTU N/A
- 52 Week Low
- FTRK $0.67
- ACTU $5.50
- 52 Week High
- FTRK $9.69
- ACTU $11.99
- Technical
- Relative Strength Index (RSI)
- FTRK N/A
- ACTU N/A
- Support Level
- FTRK N/A
- ACTU N/A
- Resistance Level
- FTRK N/A
- ACTU N/A
- Average True Range (ATR)
- FTRK 0.00
- ACTU 0.00
- MACD
- FTRK 0.00
- ACTU 0.00
- Stochastic Oscillator
- FTRK 0.00
- ACTU 0.00
About FTRK FAST TRACK GROUP
Fast Track Group is a regional entertainment-focused event management and marketing company that provides a full range of services including experiential marketing, artiste endorsement and management, movie premiere organizations, grand openings, and concerts. It also creates, develops, organizes, hosts, and manages various events and concerts.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.